Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Incyte Corporation (INCY)
Track today's live Incyte (INCY) share price, performance and key data on this page with our current NASDAQ:INCY stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Incyte share price on the NASDAQ exchange. Use the dropdown to switch exchange for the INCY share price, head to our technical summary section, which provides analysis on Incyte share price buy/sell indicators using real-time data (or discuss the Incyte (INCY) stock price today with other investors in the Incyte NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:INCY share price (ISIN: US45337C1027) to enhance your trading decisions with our free investment tools and resources.
What Is the Incyte Corporation Share Price Today?
The Incyte share price today is 119.52.
What Is the Stock Symbol for Incyte Corporation
The stock symbol (or 'ticker') for Incyte Corporation is "INCY."
What Stock Exchange Does Incyte Corporation Trade On?
Incyte Corporation is listed and trades on the NASDAQ stock exchange.
Is Incyte Corporation a Good Stock to Buy?
Determining whether Incyte (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:INCY share price (ISIN: US45337C1027) to enhance your trading decisions with our free investment tools and resources.
What Is the Incyte Corporation Share Price Today?
The Incyte share price today is 119.52.
What Is the Stock Symbol for Incyte Corporation
The stock symbol (or 'ticker') for Incyte Corporation is "INCY."
What Stock Exchange Does Incyte Corporation Trade On?
Incyte Corporation is listed and trades on the NASDAQ stock exchange.
Is Incyte Corporation a Good Stock to Buy?
Determining whether Incyte (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Currency in USD
119.52
+1.09(+0.92%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
117.00
119.53
52 wk Range
76.45
132.60
INCY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
117.00119.53
52 wk Range
76.45132.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INCY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
124.26
Upside
+3.97%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
12 analysts have revised their earnings downwards for the upcoming period
Incyte Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Incyte Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro- Incyte Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
11 Buy
15 Hold
1 Sell
Ratings:
27 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 124.26
(+3.97% Upside)
Incyte Corporation SWOT Analysis
Patent Cliff Looms | Incyte faces a $3 billion patent cliff by 2029, primarily due to Jakafi's loss of exclusivity, driving urgent need for new revenue streams |
Pipeline Progress | Explore Incyte's diverse pipeline, including promising drugs like povorcitinib, with potential to generate $600 million in hidradenitis suppurativa alone |
Market Valuation | Analyst consensus maintains a moderate buy, with price targets ranging from $52 to $96, reflecting varied views on Incyte's growth potential |
Strategic Expansion | Learn about Incyte's ambitious plan to launch ten new products by 2030, aiming to offset Jakafi's patent expiration and diversify revenue |
Incyte Corporation Earnings Call Summary for Q2/2026
- Incyte Q2 2026 EPS of $3.09 beat estimates of $1.99 by 55%; revenue of $1.67B topped forecasts of $1.42B by 17.6%, aided by $246M CMS settlement.
- Full-year 2026 sales guidance raised to $5.13B-$5.26B from $4.8B-$4.9B; OPZELURA guidance increased to $1.05B-$1.10B from $750M-$790M.
- Jakafi sales grew 7% YoY to $817M; total net product sales rose 40% to $1.49B, with underlying growth of 17% excluding settlement benefit.
- CEO emphasized strategic shift from single-product dependence to diversified platform with multiple growth drivers and late-stage pipeline assets.
- Shares rose 0.11% to $119 in premarket, near 52-week high of $120.71; upcoming catalysts include European OPZELURA decision and pipeline readouts.
Last Updated: 28/07/2026, 14:20
Read Full TranscriptEarnings
Latest Release
28/07/2026
EPS / Forecast
3.09 / 1.99
Revenue / Forecast
1.67B / 1.42B
Compare INCY to Peers and Sector
Metrics to compare | INCY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINCYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.8x | −6.1x | −0.4x | |
PEG Ratio | 0.19 | 0.15 | 0.00 | |
Price/Book | 3.8x | 1.3x | 2.6x | |
Price / LTM Sales | 4.1x | 1.8x | 3.0x | |
Upside (Analyst Target) | 1.3% | 56.8% | 54.3% | |
Fair Value Upside | Unlock | −5.7% | 8.4% | Unlock |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Incyte (NASDAQ: INCY) Share Price Today?
The Incyte stock price today is 119.52 USD.
What Stock Exchange Does Incyte (INCY) Trade On?
Incyte is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Incyte?
The stock symbol (also called a 'ticker') for Incyte is "INCY."
What Is the Current Incyte Market Capitalisation?
As of today, Incyte (NASDAQ: INCY) market cap is 24.12B USD.
What Is Incyte's (INCY) Earnings Per Share (TTM)?
The Incyte EPS is currently 7.85 (Trailing Twelve Months).
When Is the Next Incyte Earnings Date?
Incyte's next earnings report will be released on 03/11/2026.
Is INCY a Buy or Sell From a Technical Analyst Perspective?
Based on today's Incyte moving averages and other technical indicators, the daily buy/sell signal for INCY stock is Neutral.
How Many Times Has Incyte Stock Split?
Incyte has split 2 times. (See the INCY stock split history page for full effective split date and price information.)
How Many Employees Does Incyte Have?
Incyte has 2844 employees, based on their latest Companies House report.
What is the current trading status of Incyte (NASDAQ: INCY)?
As of 04/08/2026, Incyte (INCY) is trading at a share price of 119.52 USD, with a previous close of 118.43 USD. The stock has fluctuated within a day range of 117.00 USD to 119.53 USD, while its 52-week range spans from 76.45 USD to 132.60 USD.
What Is Incyte (INCY) Price Target According to Analysts?
The average 12-month price target for Incyte is 124.26 USD, with a high estimate of 155 USD and a low estimate of 86 USD. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +3.97% Upside potential.
What Is the INCY Premarket Price?
INCY's last pre-market stock price is 118.21 USD. The pre-market share volume is 1,510.00, and the stock has decreased by -0.22, or -0.19%.
What Is the INCY After Hours Price?
INCY's last after hours stock price is 119.69 USD, the stock has decreased by 1.26, or 1.06%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.